Overview

Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate

Status:
Active, not recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
This study is comparing the effectiveness of enzalutamide with or without abiraterone acetate for men with high-risk, localized prostate cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborator:
Medivation, Inc.
Treatments:
Abiraterone Acetate
Leuprolide
Prednisone